{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:14Z","timestamp":1787840354799,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Cytol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Multiple myeloma (MM), a hematological malignancy marked by clonal plasma cells in the bone marrow, occasionally presents with myelomatous effusion\u2014a rare condition with a median survival of <4 months. Central nervous system involvement (CNS-MM), characterized by plasma cell infiltration in the CNS, leptomeninges, or cerebrospinal fluid (CSF), is similarly rare and associated with dismal outcomes.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n To analyze the plasma cell involvement in body fluids and CSF in plasma cell neoplasms, correlating these findings with treatment strategies and patient outcomes.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n This retrospective study was conducted in the Oncopathology Department of a tertiary state cancer institute over 10 years (2013\u2013July 2024). It included cases of plasma cell neoplasms with confirmed involvement of body cavity fluids or CSF. Data reviewed included epidemiological profiles, biochemical and hematological findings, immunohistochemistry results, treatment regimens, and follow-up information.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A total of 16 cases demonstrated neoplastic plasma cell involvement: 12 cases in pleural fluid and 4 cases in CSF. Of these, nine cases were diagnosed with MM, five cases with plasmacytoma, and two cases with plasma cell leukemia. Treatment included chemotherapy (10 patients), palliative radiotherapy (4 patients), combined palliative radiotherapy and chemotherapy (1 patient), and curative radiotherapy with chemotherapy (1 patient). Despite these interventions, the mean survival was only 2 months.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Myelomatous involvement of effusion fluids and CSF is associated with a grim prognosis. These findings underscore the urgent need for multidisciplinary research and the development of innovative therapeutic strategies to improve outcomes for these patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/joc.joc_87_24","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:00:06Z","timestamp":1739192406000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Plasma Cells Out for a Swim! A Study on Myelomatous Involvement of Effusion Fluid and Cerebrospinal Fluid: A 10-Year Experience from a Tertiary Cancer Center"],"prefix":"10.4103","volume":"42","author":[{"given":"Sayantan","family":"De","sequence":"first","affiliation":[{"name":"Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satarupa","family":"Samanta","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"CIT0001-20250218","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"CIT0002-20250218","first-page":"103","article-title":"Pleural effusion as an initial manifestation of multiple myeloma","volume":"44","author":"Deshpande","year":"2000","journal-title":"Acta Cytol"},{"key":"CIT0003-20250218","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1159\/000527199","article-title":"Myelomatous pleural effusion: A rare case report and literature review","volume":"15","author":"Maat","year":"2022","journal-title":"Case Rep Oncol"},{"key":"CIT0004-20250218","first-page":"225","article-title":"Myelomatous pleural effusion: A case series in a single institution and literature review","volume":"31","author":"Cho","year":"2011","journal-title":"Korean J Lab Med"},{"key":"CIT0005-20250218","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3346\/jkms.2000.15.2.243","article-title":"Myelomatous effusion with poor response to chemotherapy","volume":"15","author":"Kim","year":"2000","journal-title":"J Korean Med Sci"},{"key":"CIT0006-20250218","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00234-008-0390-x","article-title":"Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay","volume":"50","author":"Cerase","year":"2008","journal-title":"Neuroradiology"},{"key":"CIT0007-20250218","doi-asserted-by":"crossref","first-page":"934240","DOI":"10.3389\/fonc.2022.934240","article-title":"Central nervous system myeloma and unusual extramedullary localizations: Real life practical guidance","volume":"12","author":"Sammartano","year":"2022","journal-title":"Front Oncol"},{"key":"CIT0008-20250218","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"CIT0009-20250218","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0970-2113.201318","article-title":"Myelomatous pleural effusion: A rare case entity reported from a tertiary care cancer center in South India","volume":"34","author":"Babu","year":"2017","journal-title":"Lung India"},{"key":"CIT0010-20250218","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1378\/chest.105.2.622","article-title":"Pleural effusion in multiple myeloma","volume":"105","author":"Rodr\u00edguez","year":"1994","journal-title":"Chest"},{"key":"CIT0011-20250218","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0970-9371.177147","article-title":"Cytology of plasma cell rich effusion in cases of plasma cell neoplasm","volume":"33","author":"Gochhait","year":"2016","journal-title":"J Cytol"},{"key":"CIT0012-20250218","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O\u2019Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"CIT0013-20250218","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2169\/internalmedicine.47.1296","article-title":"Multiple myeloma presenting initially with pleural effusion and a unique paraspinal tumor in the thorax","volume":"47","author":"Yokoyama","year":"2008","journal-title":"Intern Med"},{"key":"CIT0014-20250218","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/1040638720938687","article-title":"Chromogenic in situ hybridization for the detection of lambda and kappa immunoglobulin light chains as a potential auxiliary diagnostic technique in canine plasmacytomas","volume":"32","author":"Foiani","year":"2020","journal-title":"J Vet Diagn Invest"},{"key":"CIT0015-20250218","first-page":"59","article-title":"Myelomatous pleural effusion-A case report","volume":"5","author":"Miller","year":"2012","journal-title":"Respir Med Case Rep"},{"key":"CIT0016-20250218","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/jcrt.jcrt_1772_22","article-title":"Myelomatous pleural effusion in multiple myeloma- A rare presentation","volume":"20","author":"Pradeep","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"CIT0017-20250218","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clml.2018.12.003","article-title":"Clinicopathological profile of myelomatous pleural effusion: Single-center real-world experience and review of literature","volume":"19","author":"Yanamandra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"CIT0018-20250218","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"key":"CIT0019-20250218","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"CIT0020-20250218","doi-asserted-by":"crossref","first-page":"27028","DOI":"10.3402\/ecrj.v2.27028","article-title":"Disseminated plasma cell myeloma presenting as massive pleural effusion","volume":"2","author":"Babu","year":"2015","journal-title":"Eur Clin Respir J"},{"key":"CIT0021-20250218","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1742-6413-4-17","article-title":"Unsuspected multiples myeloma presenting as bilateral pleural effusion - A cytological diagnosis","volume":"4","author":"Dhingra","year":"2007","journal-title":"Cytojournal"},{"key":"CIT0022-20250218","first-page":"omac091","article-title":"Recurrent pleural effusion in myeloma","volume":"2022","author":"Woo","year":"2022","journal-title":"Oxf Med Case Rep"},{"key":"CIT0023-20250218","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.arbres.2014.05.009","article-title":"Pleural effusion formation in the course of myeloma","volume":"51","author":"Comert","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"CIT0024-20250218","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"CIT0025-20250218","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41375-020-0976-9","article-title":"Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age","volume":"35","author":"Mai","year":"2021","journal-title":"Leukemia"}],"container-title":["Journal of Cytology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joc.joc_87_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:13Z","timestamp":1787836873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joc.joc_87_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/joc.joc_87_24","relation":{},"ISSN":["0970-9371","0974-5165"],"issn-type":[{"value":"0970-9371","type":"print"},{"value":"0974-5165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-07-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}